The General Hospital Corporation d/b/a Massachusetts General Hospital;Millennium Pharmaceuticals, Inc.
发明人:
Cyril H. Benes,Stephen J. Blakemore,Jonathan L. Blank,Eric S. Lightcap,George J. Mulligan,Matthew C. Schu,Peter G. Smith,Jeffrey E. Settleman
申请号：
US15173393
公开号：
US20170105995A1
申请日:
2016.06.03
申请国别(地区):
US
年份:
2017
代理人:
摘要：
Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
